<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ACYCLOVIR, ACYCLOVIR SODIUM <img border="0" src="../images/pr.gif"/></span><br/>(ay-sye'kloe-ver)<br/><span class="topboxtradename">Acycloguanosine, </span><span class="topboxtradename">Zovirax<br/></span><b>Classifications:</b> <span class="classification"> antiinfective</span>; <span class="classification">antiviral</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>200 mg capsules; 400 mg, 800 mg tablets; 200 mg/5 mL suspension; 50 mg/mL injection; 5% ointment, cream</p>
<h1><a name="action">Actions</a></h1>
<p>Acyclovir is a synthetic acyclic purine nucleoside analog, derived from guanine. It reduces viral shedding and formation of
         new lesions and speeds healing time. Acyclovir triphosphate preferentially interferes with DNA synthesis of herpes simplex
         virus types 1 and 2 (HSV-1 and HSV-2) and varicella-zoster virus, thereby inhibiting viral replication.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acyclovir demonstrates antiviral activity against herpes virus simiae (B virus), Epstein-Barr (infectious mononucleosis),
         varicella-zoster and cytomegalovirus, but does not eradicate the latent herpes virus.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Parenterally for treatment of initial and recurrent mucosal and cutaneous herpes simplex virus (HSV-1 and HSV-2) infections
         in immunocompromised adults and children and for severe initial episodes of herpes genitalis in immunocompetent (normal immune
         system) patients. Used orally for treatment of initial episodes of genital herpes, for management of selected patients with
         severe recurrent episodes, and for prophylaxis to reduce frequency and severity of recurrent infections. Used topically for
         herpes labialis (cold sores), initial episodes of herpes genitalis and in non-life-threatening mucocutaneous herpes simplex
         virus infections in immunocompromised patients.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of eczema herpeticum caused by HSV localized and disseminated herpes zoster. Used orally in varicella-zoster (chickenpox)
         in immunocompetent children and adolescents. Prevention of CMV in transplant patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p> Hypersensitivity to acyclovir and valacyclovir.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation, pregnancy (category B), renal insufficiency, dehydration.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Cold Sores</span><br/><span class="rdage">Adult/Adolescents:</span> <span class="rdroute">Topical</span>
<i><img src="../images/special/greaterorequal.gif"/>12 y</i> Apply 5 times/d for 4 d<br/><br/><span class="indicationtitle">Genital Herpes Simplex</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg q4h 5 times/d, 400 mg t.i.d. for 710 d cycle <span class="rdroute">IV</span> 5 mg/kg q8h <span class="rdroute">Topical</span> Apply q3h 6 times/d for 7 d<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i> 250 mg/m<sup>2</sup> q8h, 80 mg/kg/d in 25 doses<br/><br/><span class="indicationtitle">Herpes Simplex Immunocompromised Patient</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 15 mg/kg/d divided q8h for 57 d cycle<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i> 1530 mg/kg/d divided q8h for 714 d cycle; <i><img src="../images/special/greaterorequal.gif"/>1 y,</i> 7501500 mg/m<sup>2</sup>/d, 1530 mg/kg/d divided q8h for 714 d cycle<br/><br/><span class="indicationtitle">Prophylaxis for Genital Herpes Simplex</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg 25 times/d, 400 mg t.i.d., 800 mg b.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 80 mg/kg/d in 25 divided doses<br/><br/><span class="indicationtitle">Herpes Zoster</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 800 mg q4h 5 times/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 80 mg/kg/d in 5 divided doses<br/><br/><span class="indicationtitle">Herpes Simplex Encephalitis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV</span> 15 mg/kg q8h for 1421 d cycle<br/><span class="rdage">Neonate:</span> <span class="rdroute">IV</span> 30 mg/kg/d divided q8h for 1421 d cycle<br/><span class="rdage">Premature neonate:</span> <span class="rdroute">IV</span> 20 mg/kg/d divided q12h for 1421 d cycle<br/><br/><span class="indicationtitle">Varicella Zoster</span><br/><span class="rdage">Child/</span><span class="rdage">Adolescent:</span> <span class="rdroute">PO</span> 20 mg/kg (max: 800 mg) q.i.d. for 5 d cycle initiated within 24 h of onset of rash<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> 2550 mL/min: same dose q12h; 1025 mL/min: same dose q24h<br/><br/></i></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Shake suspension well prior to use.</li>
<li>Store capsules in tight, light-resistant containers at 15°30° C (59°86° F) unless otherwise
            directed.
         </li>
</ul><span class="adminroutetype">Topical</span><br/><ul>
<li>Wash hands thoroughly before and after treatment of lesions and after handling and disposition of secretions.</li>
<li>Apply approximately ½ inch of cream or ointment ribbon for each 4 square inches of surface area. Use sufficient ointment or
            cream to completely cover lesions.
         </li>
<li>Apply topical preparation with finger cot or surgical glove.</li>
<li>Store at 15°25° C (59°78° F) unless otherwise directed.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Verify correct IV concentration and rate of infusion with physician for neonates, infants, children.</li>
<li>
                     					Note: Solutions containing benzyl alcohol are toxic to neonates.
                     				
                  </li>
<li>Directions for administration to adults follow.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span>   Reconstitute by adding 10 mL sterile water for injection to 500-mg vial to yield 50 mg/mL. Shake well. Use reconstituted solution within 12 h. Dilute to <img src="../images/special/lesserorequal.gif"/>7 mg/mL to reduce risk of renal injury and phlebitis. Example: Add
                  1 mL of reconstituted solution to 9 mL of diluent to yield 5 mg/mL. Use standard electrolyte and glucose solutions (e.g., NS, RL, D5W) for dilution. Diluted solution should be used within 24
                  h. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>   Administer over at least 1 h to prevent renal tubular damage. Rapid or bolus IV administration must be avoided. Monitor IV flow rate carefully; infusion pump or microdrip infusion set preferred. 
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Bacteriostatic water for injection,</b>
<b>albumin,</b>
<b>hetastarch,</b>
<b>dopamine,</b>
<b>dobutamine</b>. <span class="incompattype">Y-site:</span>
<b>Foscarnet,</b>
<b>TPN.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Refrigerated reconstituted solution may precipitate; however, crystals will redissolve at room temperature.</li>
<li>Store acyclovir powder and reconstituted solutions at controlled room temperature preferably at 15°30° C (59°86°
            F) unless otherwise directed by manufacturer.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Generally minimal and infrequent. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> light-headedness, lethargy, fatigue, tremors, confusion, seizures, dizziness. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea</span>. <span class="typehead">Urogenital:</span> Glomerulonephritis, renal tubular damage, <span class="speceff-life">acute renal failure</span>. <span class="typehead">Skin:</span> Rash, urticaria, pruritus, burning, stinging sensation, irritation, sensitization. <span class="typehead">Other:</span> Inflammation or phlebitis at IV injection site, sloughing (with extravasation), <span class="speceff-life">thrombocytopenic purpura/hemolytic uremic syndrome</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases acyclovir elimination; <b>zidovudine</b> may cause increased drowsiness and lethargy. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Oral dose is 1530% absorbed. <span class="typehead">Peak:</span> 1.52 h after oral dose. <span class="typehead">Distribution:</span> Distributes into most tissues with lower levels in the CNS; crosses placenta. <span class="typehead">Metabolism:</span> Drug is primarily excreted unchanged. <span class="typehead">Elimination:</span> Renally eliminated; also excreted in breast milk. <span class="typehead">Half-Life:</span> 2.55 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Observe infusion site during infusion and for a few days following infusion for signs of tissue damage.</li>
<li>Monitor I&amp;O and hydration status. Keep patient adequately hydrated during first 2 h after infusion to maintain sufficient
            urinary flow and thus prevent precipitation of drug in renal tubules. Consult physician about amount and length of time oral
            fluids need to be pushed after IV drug treatment.
         </li>
<li>Monitor for S&amp;S of: reinfection in pregnant patients; acyclovir-induced neurologic symptoms in patients with history of neurologic
            problems; drug resistance in immunocompromised patients receiving prolonged or repeated therapy; acute renal failure with
            concomitant use with other nephrotoxic drugs or preexisting renal disease.
         </li>
<li>Lab tests: Monitor baseline and periodic renal function studies, particularly with IV administration. Elevations of BUN and
            serum creatinine and decreases in creatinine clearance indicate need for dosage adjustment, discontinuation of drug, or correction
            of fluid and electrolyte balance.
         </li>
<li>Monitor for adverse effects and viral resistance with long-term prophylactic use of the oral drug.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Start therapy as soon as possible after onset of S&amp;S for best results.</li>
<li>Do not exceed recommended dosage, frequency of drug administration, or specified duration of therapy. Contact physician if
            relief is not obtained or adverse effects appear.
         </li>
<li>Cleanse affected areas with soap and water 34 times daily prior to topical application; dry well before application.
            With application to genitals, wear loose-fitting clothes over affected areas.
         </li>
<li>
            							Note: Even after HSV infection is controlled, latent virus can be activated by stress, trauma, fever, exposure to sunlight, sexual
            intercourse, menstruation, treatment with immunosuppressive drugs.
            						
         </li>
<li>Refrain from sexual intercourse if either partner has S&amp;S of herpes infection; neither topical nor systemic drug prevents
            transmission to other individuals.
         </li>
<li>Avoid topical drug contact in or around eyes. Report unexplained eye symptoms to physician immediately (e.g., redness, pain);
            untreated infection can lead to corneal keratitis and blindness.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>